Drug intelligence / Profile preview

VacV001

Development stage: Preclinical
Lead developer: VacV Biotherapeutics
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

VacV001 is an oncolytic virus therapy developed by VacV Biotheraputics (UK) Ltd. It is primarily being investigated for its potential in treating **pancreatic cancer** and **glioblastoma**. The drug exploits the vaccinia virus's ability to selectively infect and destroy cancer cells while sparing normal tissue, enhancing the body's anti-tumor response through immune activation.

Beyond the preview

Go deeper on VacV001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VacV001.

Explore the full profile